These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 2608879)

  • 1. Adult-onset mesangiocapillary glomerulonephritis: a disease with a poor prognosis.
    Chan MK; Chan KW; Chan PC; Fang GX; Cheng IK
    Q J Med; 1989 Jul; 72(267):599-607. PubMed ID: 2608879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The course and prognosis of mesangioproliferative glomerulonephritis].
    Shilov EM; Tareeva IE; Ivanov AA; Troepol'skaia OV; Krasnova TN; Varshavskiĭ VA; Proskurneva EP; Ivanova LV; Khudova IIu; Miroshnichenko NG
    Ter Arkh; 2002; 74(6):11-8. PubMed ID: 12136475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis.
    Cansick JC; Lennon R; Cummins CL; Howie AJ; McGraw ME; Saleem MA; Tizard EJ; Hulton SA; Milford DV; Taylor CM
    Nephrol Dial Transplant; 2004 Nov; 19(11):2769-77. PubMed ID: 15385635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rapidly progressive glomerulonephritis treated by apheresis. A major economic challenge].
    Branger B; Zabadani B; Vécina F; Mayor MM; Fourcade J
    Ann Med Interne (Paris); 1994; 145(5):376-80. PubMed ID: 7985954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults.
    Davison AM; Cameron JS; Kerr DN; Ogg CS; Wilkinson RW
    Clin Nephrol; 1984 Aug; 22(2):61-7. PubMed ID: 6478673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children.
    Ozdamar SO; Gucer S; Tinaztepe K
    Pediatr Nephrol; 2003 Jan; 18(1):23-8. PubMed ID: 12488986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis.
    Bahat E; Akkaya BK; Akman S; Karpuzoglu G; Guven AG
    J Nephrol; 2007; 20(2):234-45. PubMed ID: 17514629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation.
    Tang Z; Ji SM; Chen DR; Wen JQ; Chen JS; Liu ZH; Li LS
    Ren Fail; 2008; 30(6):611-6. PubMed ID: 18661411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of prognostic factors for myeloperoxidase anti-neutrophil cytoplasmic antibody- (MPO-ANCA) associated glomerulonephritis.
    Okano K; Yumura W; Nitta K; Honda K; Uchida K; Nihei H
    Clin Nephrol; 2001 Apr; 55(4):275-81. PubMed ID: 11334312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
    du Buf-Vereijken PW; Wetzels JF
    Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Membranoproliferative glomerulonephritis in patients with cryoglobulinemia complicating hepatitis C virus: report of 11 cases].
    Ben Fatma L; Ben Hamida F; Aoudia R; Goucha R; Kaaroud H; Béji S; Barbouch S; Hedri H; Abderrahim E; Elyounsi F; Ben Abdallah T; Ben Moussa F; Kheder A
    Tunis Med; 2007 Mar; 85(3):220-4. PubMed ID: 17668578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K; Yu Y; Tang Z; Liu Z; Li L
    Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Familial membranoproliferative glomerulonephritis].
    Bogdanović RM; Dimitrjević JZ; Nikolić VN; Ognjanović MV; Rodić BD; Slavković BV
    Srp Arh Celok Lek; 1999; 127(5-6):163-71. PubMed ID: 10500423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients.
    Tarantino A; De Vecchi A; Montagnino G; Imbasciati E; Mihatsch MJ; Zollinger HU; Di Belgiojoso GB; Busnach G; Ponticelli C
    Q J Med; 1981; 50(197):1-30. PubMed ID: 7267965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical course and prognostic factors in lupus nephropathy].
    Gamba G; Quintanilla L; del Bosque MD; Chew-Wong A; Correa-Rotter R
    Rev Invest Clin; 2000; 52(4):397-405. PubMed ID: 11061101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
    Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
    Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study.
    Chrysochou C; Randhawa H; Reeve R; Waldek S; Wood GN; O'Donoghue DJ; Kalra PA
    QJM; 2008 Apr; 101(4):313-6. PubMed ID: 18270227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of progression of chronic renal failure--using reciprocal of serum creatinine.
    Muthusethupathi MA; Kumar SS; Sekaran L
    J Assoc Physicians India; 1989 Mar; 37(3):213-6. PubMed ID: 2768164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presentation, prognosis and outcome of IgA nephropathy in Indian adults.
    Chacko B; John GT; Neelakantan N; Korula A; Balakrishnan N; Kirubakaran MG; Jacob CK
    Nephrology (Carlton); 2005 Oct; 10(5):496-503. PubMed ID: 16221102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.